Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
BMC Ophthalmol ; 20(1): 208, 2020 May 27.
Artículo en Inglés | MEDLINE | ID: mdl-32460732

RESUMEN

BACKGROUND: There are no data available regarding the complications associated with using antibiotic ointment at the end of intraocular surgery. This study aimed to explore the necessity of using ocular tobramycin-dexamethasone prophylactically at the end of intraocular surgery. METHODS: This was a retrospective cohort study of patients who received intraocular surgery at Tianjin Medical University General Hospital from January 2015 to December 2017. The patients were grouped according to whether they received tobramycin-dexamethasone eye ointment or not after surgery. The Tobramycin dexamethasone eye ointment was sampled to observe bacterial contamination pathogens at 0.5, 1, 1.5, 2, 2.5, 3, 6, 8, 24, 36, 48, 72, and 168 h after being opened. RESULTS: A total of 3811 eyes in 3811 patients (mean age of 63 ± 12 years) were included: 2397 eyes that received prophylactic tobramycin-dexamethasone eye ointment and 1414 eyes that did not. The overall rate of endophthalmitis was 0.08% (3/3811) in our study, all in the eye ointment group (0.12%, 3/2397); no patients developed endophthalmitis in the non-ointment group (0%, 0/1414)(P = 0.184). The anterior chamber reactions 1 day after surgery were more serious in the eye ointment group compared with the non-ointment group (all P < 0.05), but there were no statistically significant differences at 1 month postoperatively (all P > 0.05). The contamination rate was 0% at all time points over 7 days. CONCLUSION: We did not observe a statistically significant difference in the incidence of endophthalmitis in patients with or without prophylactic tobramycin-dexamethasone eye ointment. And tobramycin-dexamethasone eye ointment seemed to increase some side effects such as eye secretions increasing and foreign body feeling.


Asunto(s)
Antibacterianos/uso terapéutico , Antiinflamatorios/uso terapéutico , Endoftalmitis/prevención & control , Infecciones Bacterianas del Ojo/prevención & control , Procedimientos Quirúrgicos Oftalmológicos , Combinación Dexametasona y Tobramicina/uso terapéutico , Adulto , Anciano , Bacterias/aislamiento & purificación , Endoftalmitis/epidemiología , Endoftalmitis/microbiología , Infecciones Bacterianas del Ojo/epidemiología , Infecciones Bacterianas del Ojo/microbiología , Femenino , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad , Pomadas , Estudios Retrospectivos
3.
BMJ Case Rep ; 16(9)2023 Sep 04.
Artículo en Inglés | MEDLINE | ID: mdl-37666571

RESUMEN

A man in his 70s on regular follow-up with an ophthalmologist for 10 years presented with blurry vision in his right eye for 4 days. He was diagnosed with elevated intraocular pressure (IOP) bilaterally 18 months earlier and treated with antiglaucoma eye-drops. On direct questioning, he admitted to using fixed combination tobramycin 0.3%/dexamethasone 0.1% eye-drops frequently to relieve ocular redness and discomfort in both eyes for 3.5 years without his ophthalmologist's knowledge. Examination disclosed markedly elevated IOP, advanced optic disc cupping and tunnel vision due to steroid-induced glaucoma bilaterally. After cessation of the eye-drops and 2 weeks of antiglaucoma therapy, his IOP returned to normal and his visual field remained stable for 4 years.Our case highlights the danger of habitual self-treatment of prescription medications containing corticosteroids and the importance of taking a detailed medication history in the diagnosis and management of steroid-induced glaucoma.


Asunto(s)
Ceguera , Glaucoma , Glucocorticoides , Soluciones Oftálmicas , Combinación Dexametasona y Tobramicina , Glaucoma/inducido químicamente , Glaucoma/tratamiento farmacológico , Humanos , Masculino , Anciano , Ceguera/inducido químicamente , Combinación Dexametasona y Tobramicina/efectos adversos , Combinación Dexametasona y Tobramicina/uso terapéutico , Glucocorticoides/efectos adversos , Glucocorticoides/uso terapéutico , Soluciones Oftálmicas/efectos adversos , Soluciones Oftálmicas/uso terapéutico , Automedicación/efectos adversos , Privación de Tratamiento
4.
Pol J Vet Sci ; 24(1): 51-61, 2021 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-33847093

RESUMEN

Toxoplasmosis is one of the most important protozoa zoonotic diseases worldwide. The present study describes the clinical, seroprevalence findings with ocular toxoplasmosis and the outcome of medicinal treatment of these cats. This study was carried out on 105 cats with various ocular signs, no historical evidence of ocular trauma or drug/vaccine exposure for at least 3 months prior to admission, and without clinical or laboratory evidence of other systemic diseases. Complete case history, physical and ophthalmic examinations were carried out. The seroprevalence of Toxoplasma gondii antibodies was determined using the Toxoplasma Ab Rapid Test and Enzyme Linked Immunosorbent Assay. Out of 105 examined cats with ocular lesions, 60 cats representing 57.14% were seropositive to T. gondii. Out of these 60 cats, 15 cats (25%) had bilateral ocular abnormalities, 25 cats (41.67%) had right-sided ocular disease, and 20 cats (33.33%) had left-sided ocular disease. There were 38 cats (63.33%) with anterior uveitis, 12 cats (20%) with posterior segment involvement, 5 cats (8.33%) with anterior uveitis and anterior chamber abnormalities, 3 cats (5%) with corneal abnormalities and 2 cats (3.34%) with anterior uveitis with concurrent corneal involvement. There was a significant difference in the index values of IgM and IgG between seropositive and seronegative cats with T. gondii antibodies (p⟨0.05). There was no significant difference between the different ages, genders and breeds of cats with seroprevalence of T. gondii antibodies as well as between the age and total number of cats with seropositive and seronegative T. gondii. Out of 60 treated cats, 28 cats (46.7%), 25 cats (41.7%) and 7 cats (11.6%) showed complete, partial and poor response to treatment, respectively. In conclusion, cats showing ocular signs without obvious etiology should be examined serologically for toxoplasmosis and the seropositive cats should be treated with both specific topical and systemic treatments.


Asunto(s)
Enfermedades de los Gatos/parasitología , Oftalmopatías/veterinaria , Toxoplasmosis Animal/patología , Animales , Antibacterianos/administración & dosificación , Antibacterianos/uso terapéutico , Antiinflamatorios/administración & dosificación , Antiinflamatorios/uso terapéutico , Enfermedades de los Gatos/diagnóstico , Enfermedades de los Gatos/tratamiento farmacológico , Gatos , Clindamicina/uso terapéutico , Oftalmopatías/diagnóstico , Oftalmopatías/tratamiento farmacológico , Oftalmopatías/parasitología , Midriáticos/administración & dosificación , Midriáticos/uso terapéutico , Soluciones Oftálmicas , Inhibidores de la Síntesis de la Proteína/uso terapéutico , Combinación Dexametasona y Tobramicina/uso terapéutico , Toxoplasmosis Animal/diagnóstico , Toxoplasmosis Animal/tratamiento farmacológico , Tropicamida/uso terapéutico
5.
Eur J Ophthalmol ; 30(5): NP29-NP31, 2020 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-31155929

RESUMEN

INTRODUCTION: A case of endophthalmitis after dropless cataract surgery with intravitreal Tri-Moxi associated with severe vision loss. CASE SUMMARY: An 82-year-old male developed severe vision loss in the left eye 24 days after dropless cataract surgery with intravitreal Tri-Moxi injection. Best corrected visual acuity was hand motion in the left eye. Intraocular pressure was 13, with inferior keratic precipitates, 4 + cell with 1 mm layered hypopyon, and a plaque on the posterior capsule that blocked direct exam of the posterior segment. Ultrasonography revealed extensive vitritis without retinal or choroidal detachments. CONCLUSION: Endophthalmitis resolved and vision improved after management with vitreous tap, intravitreal and fortified topical antibiotics, and subsequent prompt pars plana vitrectomy. Vitreous sample grew fluoroquinolone-resistant staphylococcus epidermidis.


Asunto(s)
Extracción de Catarata/efectos adversos , Farmacorresistencia Bacteriana , Endoftalmitis/microbiología , Infecciones Bacterianas del Ojo/microbiología , Moxifloxacino/administración & dosificación , Infecciones Estafilocócicas/microbiología , Staphylococcus epidermidis/aislamiento & purificación , Triamcinolona/administración & dosificación , Anciano de 80 o más Años , Antibacterianos/administración & dosificación , Combinación de Medicamentos , Implantes de Medicamentos , Endoftalmitis/diagnóstico , Endoftalmitis/tratamiento farmacológico , Infecciones Bacterianas del Ojo/diagnóstico , Infecciones Bacterianas del Ojo/tratamiento farmacológico , Glucocorticoides/administración & dosificación , Humanos , Inyecciones Intravítreas , Masculino , Infecciones Estafilocócicas/diagnóstico , Infecciones Estafilocócicas/tratamiento farmacológico , Combinación Dexametasona y Tobramicina/uso terapéutico , Vancomicina/uso terapéutico , Vitrectomía
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA